Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma

Molecular Carcinogenesis

Volumn 54, Issue 1, 2015, Pages 35-49

  Okamoto, Takako ^a,b   Mandai, Masaki ^a   Matsumura, Noriomi ^a   Yamaguchi, Ken ^a   Kondoh, Hiroshi ^a   Amano, Yasuaki ^a   Baba, Tsukasa ^a   Hamanishi, Junzo ^a   Abiko, Kaoru ^a   Kosaka, Kenzo ^a   Murphy, Susan K ^b   Mori, Seiichi ^c   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CANCER INSTITUTE   (Japan)

Author keywords

Glucose metabolism; HNF1 ; Ovarian clear cell carcinoma

Indexed keywords

GLUCOSE TRANSPORTER 1; HEPATOCYTE NUCLEAR FACTOR 1BETA; LACTIC ACID; SHORT HAIRPIN RNA; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLUCOSE; HNF1B PROTEIN, HUMAN; SLC2A1 PROTEIN, HUMAN;

AEROBIC GLYCOLYSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE REPRESSION; GENETIC ASSOCIATION; GLUCOSE TRANSPORT; GLUT1 GENE; HNF1B GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF QUANTITATION; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; ADENOCARCINOMA; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GLYCOLYSIS; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; OVARIAN NEOPLASMS;

EID: 84914677712     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22072     Document Type: Article

References (37)

1. Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I. Ovarian cancer in endometriosis: Molecular biology, pathology, and clinical management. Int J Clin Oncol 2009; 14:383-391.
2. Kobayashi H. Ovarian cancer in endometriosis: Epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol 2009; 14:378-382.
3. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008; 99:653-658.
4. Kobayashi H, Sumimoto K, Moniwa N, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: A cohort study in Shizuoka, Japan. Int J Gynecol Cancer 2007; 17:37-43.
5. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88:2584-2589.
6. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-417.
7. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008; 14:32-40.
8. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010; 29:1741-1752.
9. Bach I, Mattei MG, Cereghini S, Yaniv M. Two members of an HNF1 homeoprotein family are expressed in human liver. Nucleic Acids Res 1991; 19:3553-3559.
10. Bingham C, Hattersley AT. Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1beta. Nephrol Dial Transplant 2004; 19:2703-2708.
11. Maestro MA, Cardalda C, Boj SF, Luco RF, Servitja JM, Ferrer J. Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-cell function and growth. Endocr Dev 2007; 12:33-45.
12. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003; 163:2503-2512.
13. Matsumura N, Mandai M, Okamoto T, et al. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci 2010; 101:2658-2663.
14. Wakasugi M, Matsuura K, Nagasawa A, et al. DDB1 gene disruption causes a severe growth defect and apoptosis in chicken DT40 cells. Biochem Biophys Res Commun 2007; 364:771-777.
15. Shi DY, Xie FZ, Zhai C, Stern JS, Liu Y, Liu SL. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells. Mol Cancer 2009; 8:32.
16. Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65:177-185.
17. Kato N, Toukairin M, Asanuma I, Motoyama T. Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): A marker for ovarian clear cell carcinoma. Diagn Cytopathol 2007; 35:193-197.
18. Kao YC, Lin MC, Lin WC, Jeng YM, Mao TL. Utility of hepatocyte nuclear factor-1beta as a diagnostic marker in ovarian carcinomas with clear cells. Histopathology 2012; 61:760-768.
19. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: Lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol 2012; 20:580-587.
20. Kato N, Tamura G, Motoyama T. Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary. Virchows Arch 2008; 452:175-180.
21. Chang JT, Nevins JR. GATHER: A systems approach to interpreting genomic signatures. Bioinformatics 2006; 22:2926-2933.
22. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330:1340-1344.
23. Mentis AF, Kararizou E. Metabolism and cancer: An up-to-date review of a mutual connection. Asian Pac J Cancer Prev 2010; 11:1437-1444.
24. DeBerardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med 2008; 10:767-777.
25. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009; 9:1084-1101.
26. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: Why do cancers have high glycolysis? J Bioenerg Biomembr 2007; 39:251-257.
27. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007; 39:231-234.
28. Stany MP, Vathipadiekal V, Ozbun L, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS ONE 2011; 6:e21121.25.
29. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15:501-513.
30. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314.
31. Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med 2011; 89:237-245.
32. Kondoh H. Cellular life span and the Warburg effect. Exp Cell Res 2008; 314:1923-1928.
33. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15:6479-6483.
34. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis-The seventh hallmark of cancer. Cell Mol Life Sci 2008; 65:3981-3999.
35. Fritz V, Fajas L. Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene 2010; 29:4369-4377.
36. Kondoh H, Lleonart ME, Bernard D, Gil J. Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization. Histol Histopathol 2007; 22:85-90.
37. Ruckenstuhl C, Buttner S, Carmona-Gutierrez D, et al. The Warburg effect suppresses oxidative stress induced apoptosis in a yeast model for cancer. PLoS ONE 2009; 4:e4592.